Biosimilars | Overview & Forecast | G7 | 2019

launch Related Market Assessment Reports

• Biosimilars – Forecast – Ophthalmology

  September 2023

  In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the…

• Biosimilars – Forecast – Overview Of Biosimilar Forecasts

  In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

• Biosimilars – Forecast – Immunology

  In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

• Biosimilars – Forecast – Forecast Methodology And General Market Assumptions

  In 2021, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $130 billion in the major pharmaceutical markets under…

• Biosimilars – Forecast – Oncology

  In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…